Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Amortization of Deferred Charges (2016)

Ekso Bionics Holdings (EKSO) has disclosed Amortization of Deferred Charges for 4 consecutive years, with -$9000.0 as the latest value for Q3 2016.

  • On a quarterly basis, Amortization of Deferred Charges changed 0.0% to -$9000.0 in Q3 2016 year-over-year; TTM through Sep 2016 was -$36000.0, a 2.84% increase, with the full-year FY2016 number at -$36000.0, up 2.7% from a year prior.
  • Amortization of Deferred Charges was -$9000.0 for Q3 2016 at Ekso Bionics Holdings, roughly flat from -$9000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of -$9000.0 in Q2 2015 to a low of -$10000.0 in Q1 2015.
  • A 4-year average of -$9109.8 and a median of -$9000.0 in 2015 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: decreased 10.47% in 2015, then rose 10.0% in 2016.
  • Ekso Bionics Holdings' Amortization of Deferred Charges stood at -$9052.0 in 2013, then changed by 0.0% to -$9052.0 in 2014, then increased by 0.57% to -$9000.0 in 2015, then changed by 0.0% to -$9000.0 in 2016.
  • Per Business Quant, the three most recent readings for EKSO's Amortization of Deferred Charges are -$9000.0 (Q3 2016), -$9000.0 (Q2 2016), and -$9000.0 (Q1 2016).